Shares in Movetis NV edged up slightly on their first day of trading on the NYSE Euronext Exchange in Brussels Friday, following an IPO that raised gross proceeds of €85 million (US$126 million). The company priced the offering of 6,938,776 new shares at €12.25, slightly below the mid-point of the indicative range of €11.25 to €14.25 it published at the outset of the book-building period. (BioWorld International) Read More
No Abstract BioWorld International CorrespondentLONDON - Biocompatibles International plc moved onto the next stage of its collaboration with AstraZeneca plc, agreeing to a schedule for the Phase I and Phase II trials of the Type II diabetes drug CM3, and thus triggering a further €4.3 million (US$6.4 million) payment from the pharma company. Read More
